Patients with atrial fibrillation need to take anticoagulants such as rivaroxaban for life, except for those who do not need anticoagulation or who have successfully recovered from atrial fibrillation.
Patients with atrial fibrillation are prone to thromboembolism, especially cerebral embolism, which is the most harmful, often life-threatening, and seriously affects the patient’s quality of life. Patients with atrial fibrillation can actively prevent thromboembolism through anticoagulation.
For non-valvular atrial fibrillation, new oral anticoagulants (NOACs) such as dabigatran etexilate, rivaroxaban, apixaban, etc. can be used. Patients should be on lifelong medication to prevent thromboembolism. Please follow your doctor’s instructions for specific medications.
Adverse reactions to rivaroxaban include risk of bleeding, granulocyte deficiency, thrombocytopenia, hypersensitivity reactions, anaphylactic reactions, anaphylaxis, angioedema, jaundice, cholestasis, and hepatitis. It is contraindicated for those who are allergic to the product, those with markedly active bleeding, those with abnormal coagulation function, pregnant and lactating women.
If long-term anticoagulation is not suitable, or stroke or embolism still occurs on the basis of long-term standardized anticoagulation, percutaneous left heart ear block may be considered.
If there is any discomfort, consult a doctor and follow the medical advice.